UAE-based biotech startup BioSapien has extended its pre-Series A funding round to over $8m, with new investment from VC firm Globivest which joins existing investors including Global Ventures, Golden Gate Ventures, and Dara Holdings.
The startup is developing a 3D-printed localised cancer treatment platform aligned with the UAE’s health innovation goals.
BioSapien previously raised $5.5m in December 2024 and increased its funding to $7m in January 2025.
Gulf Economist Staff Writer